Clinical Trials
7
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:4
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (57.1%)Phase 2
3 (42.9%)Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 25
- Registration Number
- NCT02899286
- Locations
- 🇭🇰
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
Phase 1
Completed
- Conditions
- MelanomaProstate Adenocarcinoma
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 23
- Registration Number
- NCT02285101
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, cCARE, San Diego, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 27
- Registration Number
- NCT02089763
- Locations
- 🇭🇰
Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong, Hong Kong
Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 17
- Registration Number
- NCT02089633
- Locations
- 🇭🇰
The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Phase 1
Terminated
- Conditions
- LymphomaLeukemia
- Interventions
- Drug: Recombinant human arginase 1 Peg5000
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Bio-Cancer Treatment International Limited
- Target Recruit Count
- 1
- Registration Number
- NCT01551628
- Locations
- 🇨🇳
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China
- Prev
- 1
- 2
- Next
News
No news found